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Abstract 
Object Pilocytic astrocytomas are rare tumours in adults. Presentation, management and 
prognostic factors are poorly characterised. Methods Retrospective single centre study from 
2000 - 2016. Results 50 cases were identified (median age 29 years; range 16–76). Symptoms 
at presentation were neurological deficit (n=21), headache (n=18) and seizures (n=6). Five 
were incidental findings. Five patients had hydrocephalus at presentation and required 
emergent management, two by endoscopic third ventriculostomy and three by external 
ventricular drain. Symptoms were present for a median of 16 weeks (range 1 week to 34 
years). Surgery consisted of gross total resection (n=23), subtotal resection (n=21) or biopsy 
(n=6). Progression occurred in 20 patients at a median time of 7 years following surgery and 
was asymptomatic in just over half of these cases. A greater degree of resection (complete vs. 
subtotal) was associated with longer time to progression (Kaplan-Meier analysis, log rank test 
= 3.58, p=0.059). At their first progression 12 patients underwent re-resective surgery and the 
remainder received radiotherapy. The median 5-year survival was 80%. Conclusions In adult 
patients with a pilocytic astrocytoma, a macroscopic resection should be the aim at the first 
resective operation. Emergency management of hydrocephalus may be required in the first 
instance. 
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Introduction 
Pilocytic astrocytoma is the most common childhood glioma but is infrequently seen in 
adults. They are described by the 2016 WHO Classification of Tumours of the Central 
Nervous System as borderline benign/malignant entities with uncertain behaviour patterns 
7,11,12. Derived from neuroepithelial tissue these astrocytic tumours are assigned grade I status 
to denote their well circumscribed nature 11. They tend to be slowly growing, cystic and 
preferentially located in cerebral midline structures such as the cerebellum, hypothalamus, 
brain stem and optic pathways 11.  Histologically they are characterised by a biphasic pattern 
with varying proportions of compacted bipolar cells with Rosenthal fibres and loose textured 
multipolar cells with microcysts and granular bodies 3. Whilst surgery may be curative, 
complete resection is not always feasible and due to the relative rarity of this disease in 
adults, there are few publications on the most effective management strategies and 
subsequent patient outcomes 7,19. The aim of this study was to investigate the clinical 
presentation, management and outcomes in adults with pilocytic astrocytoma.   
 
Methods 
Patients with a diagnosis of pilocytic astrocytoma were identified from histopathology 
records at a single institution. The histology was classified according to the WHO criteria in 
use at the time of diagnosis. Patients aged over 16 years are treated at the adult service in our 
region and therefore such patients treated between January 2000 and February 2016 were 
included. Medical records, operative notes, imaging reports and correspondence were 
examined and data gathered on age, gender, presenting symptoms and neurological signs. 
Tumour location, size and presence of hydrocephalus were determined from computed 
tomography and magnetic resonance imaging scans. Surgery, indication and extent of 
resection were obtained from the operative notes and post-operative imaging. Extent of 
resection was categorised as gross total resection, subtotal resection or biopsy. Patient 
management and adjuvant therapy was discussed at weekly multidisciplinary tumour 
meetings (or tumour boards).  Complications were recorded from medical notes. 
Tumour progression was defined radiologically by RANO criteria and confirmed clinically 
by review and discussion at MDT. Progression free survival (PFS) was measured as time 
from diagnosis to first progression and overall survival (OS) was taken as time from 
diagnosis to tumour death. Cases where the patient died before progression were censored at 
the last brain scan and those who were lost to follow up or died of other causes were censored 
at the last clinic appointment recorded. Data were analysed using SPSS version v22 (IBM 
co., 2011). For analysis of PFS and OS, the Kaplan-Meier product limit method was used and 
survival curves plotted. Log rank tests were applied to detect differences between paired 
groups. For multivariate analysis Cox’s method was used to compare competing hazards. 
Standard tests were used for comparisons of means and analysis of variance. The level of 
significance was set at 95% to reject the null hypothesis and all p-values and confidence 
intervals are stated. 
 
Results 
Presenting features  
Fifty patients were identified with a median age of 29 years (range 16–76). There were 29 
male and 21 female patients. Symptoms at presentation were neurological deficit (n=21), 
headache (n=18), seizures (n=6) and five were incidental. Five patients had hydrocephalus at 
presentation and required emergency management, two by endoscopic third ventriculostomy 
(ETV) and three by external ventricular drain (EVD). Symptoms were present for a median 
of 16 weeks (range 1 week to 34 years). Tumours were located in cerebellar hemisphere 
(n=14), intraventricular (n=13), brainstem (n=10), lobar (n=9) and hypothalamus (n=4).  
Surgical treatment 
Surgery consisted of gross total resection (GTR) (n=22), subtotal resection (STR) (n=20) or 
biopsy (n=8). No hypothalamic tumours and only one brainstem tumour underwent GTR 
although there was no statistical association of location with degree of resection (Fisher’s 
exact test 17.8, p = 0.324). Surgical complications included three cases of transient 
neurological deficits (two upper limb weakness and one 6th nerve palsy) and two permanent 
neurological deficits (one permanent loss of visual acuity, one permanent cognitive 
impairment). Other surgical morbidity included two superficial and four deep wound 
infections which required antibiotic treatment and 5 CSF leaks that required suturing but not 
temporary or permanent CSF diversion. Patients with permanent neurological deficit were 
significantly older (t-test 2.08, p=0.043) at the time of surgery but had not had more 
extensive resection (Fisher’s exact test 2.48, p=0.292) nor were their tumours in different 
locations (Fisher’s exact test 3.60, p=0.774) compared to those with no complications.  
Adjuvant therapy 
All 22 patients who underwent GTR were observed with serial MRI scans at 6-12 month 
intervals at the operating neurosurgeon’s discretion. None of these patients received adjuvant 
post-operative radiotherapy or interstitial radiosurgery. After biopsy or subtotal resection the 
decision to treat with adjuvant radiotherapy was made by the neuro-oncologist after 
multidisciplinary discussion based on imaging findings, patient’s performance status and age. 
Of those 28 patients, 18 were monitored with 6-12 monthly MRI as for gross total resection 
cases and six received fractionated radiotherapy (50 - 54 Gy in 30 fractions). Three patients 
were treated with interstitial radiosurgery by iodine-125 seeds inserted at the time of biopsy 
(one seed with activity of 9.4mCi to cover the tumour with 60Gy isodose line implanted for 
14 days, one seed of 14.2mCi to cover the tumour with 60Gy isodose and one with regime 
not specified but likely to be similar).  
Progression and survival  
Tumour progression occurred in 20 patients at a median of 7 years (95% CI 4.5 – 9.5) 
following surgery (Figure 1a). Only 4 of the 22 patients who underwent GTR  progressed, at 
a median of 1 year (maximum of 3 years) following surgery. By comparison 12 of 20 patients 
who underwent STR progressed at a median of 7 years for those who received adjuvant 
radiotherapy versus 5 years for those who were simply observed. GTR was associated with a 
trend to longer progression free survival (PFS) than STR although this did not reach 
significance (Kaplan-Meier analysis, log rank test = 3.58, p=0.059), illustrated in figure 1b. 
Post hoc we further divided the STR group by assessment of the available post op scans, 
MDT reports and operation notes into two groups, dependent on how much residual was left, 
>25% of the original tumour (n=10) or <25% (n=7). There was no significant difference in 
PFS between these subgroups (log rank test = 1.49, p = 0.222) although both had 
significantly longer PFS than biopsy cases (p=0.022 and 0.005 respectively). Even dividing 
STR into just two subgroups there were only 3 events (the rest were censored) in one group 
so further subdivision of this category was not deemed statistically justified. Of the other 
factors assessed, age (HR=1.02, p=0.557), tumour location (pooled log rank = 3.864, df = 6, 
p = 0.695) and adjuvant therapy (pooled log rank = 0.96, df = 2, p=0.619) were not 
significantly associated with PFS after surgery. For those patients receiving biopsy only, 
interstitial radiosurgery at the time of biopsy was not associated with the incidence of 
progression (Fisher’s exact test 1.494, p=0.51). 
At first progression, seven patients who had undergone STR or biopsy at their first 
presentation, including two who had received adjuvant radiotherapy, underwent resection 
then observation with serial scans. Three were originally STR but achieved GTR and three 
were originally biopsy but achieved STR (with at least 75% tumour resection looking at the 
imaging). In this group there was one patient with a major surgical complication 
(intraventricular haemorrhage and permanent neurological deficit) and three with minor 
complications (wound leak, infection, and hospital acquired pneumonia). Five patients who 
had undergone GTR or STR followed by observation at their first presentation underwent a 
further subtotal resection to the progressive tumour followed by fractionated radiotherapy (54 
Gy / 30#). There were no major surgical complications in this group, minor complications 
were wound infection and DVT. One patient did not receive adjuvant radiotherapy because of 
tumour proximity to the optic nerve. One patient’s treatment after progression was unknown 
as surgery was performed elsewhere.  
Two patients who had undergone biopsy and interstitial radiosurgery and one who had 
undergone biopsy only went on to have a further biopsy (to confirm no change in histology) 
and interstitial radiosurgery with radioiodine seeds when they progressed and one of those 
developed radiation necrosis. One patient with STR initially who then progressed rapidly had 
radiotherapy (50.4 Gy in 28 #). One patient underwent palliative shunt insertion and was not 
fit for further therapy. 
Second progression occurred in four patients out of 20 at a median of 1 year from their first 
progression and only two of these went on to have another craniotomy. Patient flow is seen in 
Figure 2. The 5-year overall survival for this series was 80%; median follow up varied greatly 
and was 3.5 years in the whole cohort (range 0 – 21 years) but 4 years (range 0 – 12 years) in 
the group with GTR at first operation 
Discussion 
 
Introduction – presentation/symptomatology/tumour location 
 
Pilocytic astrocytomas are benign tumours, occurring mainly in children, which have 
the potential for cure.  They are described pathologically as as exhibiting nuclear 
abnormalities in all cases and endothelial proliferation in many and are World Health 
Organisation (WHO) grade I 2,12.  Adults are also affected, and previous reports demonstrate 
a median adult age of 31 years7,8,17, similar to our series.  More males than females develop 
the tumour7,8,17.  Presentations of headache and or incidental finding predominate in the 
current study rather than previous series which report neurological deficit7, which may be due 
to the increased availability of MRI, and the drive for earlier scanning in patients with 
potential symptoms of a brain tumour 4,6.  They are typically T2 hyperintense enhancing 
nodular lesions in the cerebellum or periventricular area18. 
Tumour location dictates the surgical strategy and the extent of resection that can be 
achieved. Complete resection is difficult in some locations, particularly deep midline 
locations, so may promote the use of non-invasive or less aggressive interventions 19. 
Tumours in the cerebellar hemisphere and intraventricular regions predominated, although 
previous studies have described cerebral lobes, brainstem, and spinal cord8. The current study 
excluded spinal cord tumours. 
 
Therapeutic intervention  
Pilocytic astrocytoma is amenable to a range of therapeutic interventions including surgery, 
radiotherapy and chemotherapy, yet there are no randomised trials and allowing for the idea 
of maximal safe resection, there is little consensus on how they should be employed to ensure 
optimal patient outcomes. The emergency management of hydrocephalus may be required in 
the first instance, but once stable, the present study suggests that the best outcomes for 
patients are obtained with complete resection.  Use of image guidance, Multidisciplinary 
Team Meetings (MDT or tumour boards) to aid in surgical decision making, intraoperative 
ultrasound and / or intraoperative MRI by surgeons routinely performing cranial oncology 
surgery should be considered20.  If residual disease is found on an early post op scan, early 
reoperation should be considered as long as surgical risks allow. Otherwise, patients with 
residual disease may be observed, and only offered radiotherapy or radiosurgery after 
evidence of progression 2. Defining the degree of residual disease is problematic and we 
found disagreement depending on sequences and techniques used. We therefore binned 
surgical treatment into only 3 categories: gross total resection, subtotal and biopsy. Ideally, 
some formal regime of imaging would allow comparison of pre and post-operative enhancing 
tumour volume and the volume of tumour resected should be calculated in order to 
characterise the relation of degree of residual to progression and survival. This is particularly 
useful if there is a cut-off past which the risk of progression greatly increases.  
Operative risks are higher at surgery following progression.  Few repeat surgeries 
achieve complete resection (although a small number did here for reasons that are not 
discernible by retrospective review only), and most ultimately have radiotherapy7. Previous 
authors have suggested that fit individuals should be offered appropriate salvage therapies in 
anticipation of long term survival and proven good neurological outcomes1,7, although the 
current series suggests interventions on those who progress are relatively unsatisfactory.  As 
most patients are observed, and radiation treatment reserved for progression, reports on the 
outcome after radiotherapy are rare and include only small numbers of patients.  Adjuvant 
radiotherapy as first line treatment is reported as significantly increasing progression-free 
survival rates over observation alone, although overall survival is not altered 7,10. Malignant 
transformation following radiotherapy of pilocytic astrocytomas is reported 5,15,17.  The role 
of chemotherapeutic agents, proton beam therapy, and other newer novel treatments is not 
clear.   
 
Overall survival 
Five and 10 year progression free rates of 63% and 35% and overall survival rates 
95% and 85% respectively are reported13 7.  The current study reports a slightly lower 5-year 
survival of 80% possibly reflecting differences in demographics, therapeutic interventions, 
and the fact that advances in medical technology and practice occurring over large study time 
frame may confound data.  Long term follow up beyond that reported in the recent SEER 
database study confirms that recurrence after 10, 15 or 20 years is rare8 therefore it is argued 
that if there is no residual enhancing disease at 5 years after complete resection then patients 
can be safely discharged; this study confirms this is problematic in practice and many patients 
in this series were followed up for longer than this, up to a maximum of 12 years even after 
GTR. 
 
Future directions 
Molecular tumour charecteristics are being developed.  Standardized assessment of 
proliferating cell nuclear antigen (PCNA) to investigate tumour cell growth kinetics in 
pilocytoc astrocytomas may be a useful, independent indicant of biological behaviour 14. 
Whole genome interrogation has shown single point aberrations of the mitogen-activating 
protein kinase (MAPK) pathway in nearly all cases9. The most commonly observed 
mechanism gives rise to a transforming fusion protein with BRAF kinase domain9. Whilst not 
yet commonplace, array comparative genomic hybridization (aCGH) analysis is being used to 
identify a variety of novel, subtle genomic changes which may liberate clinically useful 
diagnostic and therapeutic biomarkers 16. Although specific to supratentorial tumours, the 
histological characteristis of adult pilocytic astrocytomas are known to include nuclear 
abnormalities, mitoses and endothelial proliferation2. 
The importance of optimal pilocytic astrocytoma management in increasing patients’ 
quantity and quality of life is clear. However there is an apparent lack of 
progression/recurrence predictors and modern, consistent, authoritative evidence on the 
matter, especially in terms of histological or genetic factors and appropriate therapeutic 
interventions. As such, national, prospective, adult specific future clinical studies are 
warranted to determine the role of adjuvant radiotherapy and chemotherapy. 
 
Conclusion 
This single centre series supports the growing consensus that in adult patients with a pilocytic 
astrocytoma, a macroscopic resection should be the aim at the first resective operation and 
early second look surgery for any residual on postoperative imaging should be considered. 
Patients with no residual enhancing disease at 5 year follow up may be discharged but this 
does not appear to routinely happen in clinical practice.  
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Figure 1a – Progression free survival plot 
 
Figure 1b – Progression free survival plot by degree of resection 
 
 
 
Figure 2 - Patient flow  
 
 
ETV - Endoscopic Third Ventriculostomy 
EVD - External Ventricular Drain 
 
 
